12th Januar 2025
Neuigkeiten
Bleiben Sie auf dem neuesten Stand. Hier finden Sie unsere Pressemitteilungen. Hier können Sie sich über bevorstehende Veranstaltungen informieren, an denen Curium teilnehmen wird.
17th Juni 2024
Curium gibt erste kommerzielle Dosen von Pylclari® – ¹⁸F-PSMA PET Radiopharmazeutikum in Österreich bekannt
6th Mai 2024
Curium: Erste kommerzielle Dosen von PYLCLARI® in Deutschland verfügbar – ein innovativer 18F-PSMA PET tracer für Patienten mit Prostatakrebs
8th April 2024
Curium plans to significantly expand Lutetium-177 capacity and PET footprint with agreement to acquire Eczacibaşi-Monrol
25th Oktober 2023
Curium und PIUR IMAGING kündigen eine Partnerschaft für die Schilddrüsenbildgebung in Deutschland an, um tomographische 3D-Ultraschallösungen zu ermöglichen
7th September 2023
Curium announces exclusive distribution agreement in Switzerland with b.e. Imaging for PYLCLARI™, an innovative 18F-PSMA PET tracer indicated in adults with prostate cancer
15th August 2023
Curium announces achievement of co-primary endpoints in phase 2 of its phase 1/2 SOLAR clinical trial imaging men with histologically-proven prostate cancer using copper Cu 64 PSMA I&T
28th Juli 2023
Curium receives marketing authorization in the EU for Pylclari™, an innovative 18F-PSMA PET tracer indicated in adults with prostate cancer
25th Juli 2023
Curium announces license and development agreement with Lantheus for AI-based PSMA PET software in Europe
21st Juli 2023
Curium announces publication of [18F]DCFPyL versus [18F]fuoromethylcholine results from European phase III Study (PYTHON trial)
21st Juli 2023
Curium announces publication of [18F]DCFPyL versus [18F]fuoromethylcholine results from European phase III Study (PYTHON trial)
26th Mai 2023
Curium receives positive CHMP opinion of PYLCLARI® for primary staging of patients with high-risk PCa prior to initial curative therapy and to localize recurrence of PCa in patients with a suspected recurrence based on increasing serum Prostate-Specific Antigen (PSA) levels after primary treatment with curative intent
23rd Mai 2023
Curium announces last patient enrolled in their Phase 1/2 SOLAR clinical trial imaging men with histologically-proven metastatic prostate cancer using copper Cu 64 PSMA I&T
2nd Mai 2023
Curasight and Curium announce global partnership for uTRACE® in prostate cancer
14th März 2023
Curium confirms no supply challenges in North America and Europe for its ECLIPSE Phase 3 clinical trial
2nd März 2023
Innovation and growing demand for nuclear medicine drives Curium expansion and 10-year commitment to St. Louis, MO
21st Dezember 2022
Curium’s 14 million patients to benefit from regular supply of Mo-99 and TC-99
24th November 2022
Curium’s Customers to benefit from Mo-99 Production restart
22nd November 2022
Curium Announces New Indication for Ioflupane I 123 Injection in the U.S.
9th November 2022